These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 17451844)
1. Behavioral consequences of ovarian atrophy and estrogen replacement in the APPswe mouse. Golub MS; Germann SL; Mercer M; Gordon MN; Morgan DG; Mayer LP; Hoyer PB Neurobiol Aging; 2008 Oct; 29(10):1512-23. PubMed ID: 17451844 [TBL] [Abstract][Full Text] [Related]
2. Estrogen treatment improves spatial learning in APP + PS1 mice but does not affect beta amyloid accumulation and plaque formation. Heikkinen T; Kalesnykas G; Rissanen A; Tapiola T; Iivonen S; Wang J; Chaudhuri J; Tanila H; Miettinen R; Puoliväli J Exp Neurol; 2004 May; 187(1):105-17. PubMed ID: 15081593 [TBL] [Abstract][Full Text] [Related]
3. The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. Rockenstein E; Adame A; Mante M; Moessler H; Windisch M; Masliah E J Neural Transm (Vienna); 2003 Nov; 110(11):1313-27. PubMed ID: 14628195 [TBL] [Abstract][Full Text] [Related]
4. Effects of continuous and intermittent estrogen treatments on memory in aging female mice. Gresack JE; Frick KM Brain Res; 2006 Oct; 1115(1):135-47. PubMed ID: 16920082 [TBL] [Abstract][Full Text] [Related]
5. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Melnikova T; Savonenko A; Wang Q; Liang X; Hand T; Wu L; Kaufmann WE; Vehmas A; Andreasson KI Neuroscience; 2006 Sep; 141(3):1149-62. PubMed ID: 16753269 [TBL] [Abstract][Full Text] [Related]
6. Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer's disease. Amtul Z; Wang L; Westaway D; Rozmahel RF Neuroscience; 2010 Aug; 169(2):781-6. PubMed ID: 20493928 [TBL] [Abstract][Full Text] [Related]
7. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. Wilcock DM; Alamed J; Gottschall PE; Grimm J; Rosenthal A; Pons J; Ronan V; Symmonds K; Gordon MN; Morgan D J Neurosci; 2006 May; 26(20):5340-6. PubMed ID: 16707786 [TBL] [Abstract][Full Text] [Related]
8. Effects of progesterone administration and APPswe+PSEN1Deltae9 mutation for cognitive performance of mid-aged mice. Frye CA; Walf AA Neurobiol Learn Mem; 2008 Jan; 89(1):17-26. PubMed ID: 17988898 [TBL] [Abstract][Full Text] [Related]
9. Pomegranate extract modulates processing of amyloid-β precursor protein in an aged Alzheimer's disease animal model. Ahmed AH; Subaiea GM; Eid A; Li L; Seeram NP; Zawia NH Curr Alzheimer Res; 2014; 11(9):834-43. PubMed ID: 25274111 [TBL] [Abstract][Full Text] [Related]
10. Behavioural Phenotyping of APPswe/PS1δE9 Mice: Age-Rrelated Changes and Effect of Long-Term Paroxetine Treatment. Olesen LØ; Bouzinova EV; Severino M; Sivasaravanaparan M; Hasselstrøm JB; Finsen B; Wiborg O PLoS One; 2016; 11(11):e0165144. PubMed ID: 27814403 [TBL] [Abstract][Full Text] [Related]
11. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. McClean PL; Hölscher C Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293 [TBL] [Abstract][Full Text] [Related]
12. Estrogen alters amyloid precursor protein as well as dendritic and cholinergic markers in a mouse model of Down syndrome. Granholm AC; Sanders L; Seo H; Lin L; Ford K; Isacson O Hippocampus; 2003; 13(8):905-14. PubMed ID: 14750653 [TBL] [Abstract][Full Text] [Related]
13. Comparative studies using the Morris water maze to assess spatial memory deficits in two transgenic mouse models of Alzheimer's disease. Edwards SR; Hamlin AS; Marks N; Coulson EJ; Smith MT Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):798-806. PubMed ID: 25115283 [TBL] [Abstract][Full Text] [Related]
14. Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain. Arendash GW; Lewis J; Leighty RE; McGowan E; Cracchiolo JR; Hutton M; Garcia MF Brain Res; 2004 Jun; 1012(1-2):29-41. PubMed ID: 15158158 [TBL] [Abstract][Full Text] [Related]
15. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease. Guo C; Wang T; Zheng W; Shan ZY; Teng WP; Wang ZY Neurobiol Aging; 2013 Feb; 34(2):562-75. PubMed ID: 22717236 [TBL] [Abstract][Full Text] [Related]
17. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. Olcese JM; Cao C; Mori T; Mamcarz MB; Maxwell A; Runfeldt MJ; Wang L; Zhang C; Lin X; Zhang G; Arendash GW J Pineal Res; 2009 Aug; 47(1):82-96. PubMed ID: 19538338 [TBL] [Abstract][Full Text] [Related]
18. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease. Zhang W; Hao J; Liu R; Zhang Z; Lei G; Su C; Miao J; Li Z Behav Brain Res; 2011 Sep; 222(2):342-50. PubMed ID: 21513747 [TBL] [Abstract][Full Text] [Related]
19. Age-dependent increase in lysosome-associated membrane protein 1 and early-onset behavioral deficits in APPSL transgenic mouse model of Alzheimer's disease. Hashimoto T; Ogino K; Shin RW; Kitamoto T; Kikuchi T; Shimizu N Neurosci Lett; 2010 Jan; 469(2):273-7. PubMed ID: 20025930 [TBL] [Abstract][Full Text] [Related]
20. The cognitive effects of ovariectomy and estrogen replacement are modulated by aging. Savonenko AV; Markowska AL Neuroscience; 2003; 119(3):821-30. PubMed ID: 12809703 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]